Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results

Ventyx Biosciences (NASDAQ:VTYXGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.07, MarketWatch Earnings reports.

VTYX traded up $0.38 on Friday, reaching $14.91. The company had a trading volume of 207,991 shares, compared to its average volume of 150,796. The business has a 50 day simple moving average of $13.44 and a 200 day simple moving average of $15.42. Ventyx Biosciences has a 52-week low of $9.50 and a 52-week high of $26.00.

Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 26th. Oppenheimer assumed coverage on shares of Ventyx Biosciences in a research note on Tuesday, February 1st. They issued an “outperform” rating and a $30.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a research note on Thursday, March 31st. They issued a “buy” rating for the company. Credit Suisse Group initiated coverage on shares of Ventyx Biosciences in a research report on Monday, May 9th. They set an “outperform” rating and a $53.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a research report on Thursday, March 31st. They set a “buy” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Ventyx Biosciences presently has an average rating of “Buy” and an average target price of $40.50.

Several large investors have recently made changes to their positions in the stock. Citigroup Inc. bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $56,000. California State Teachers Retirement System bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $114,000. Wells Fargo & Company MN bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $121,000. Deutsche Bank AG bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $126,000. Finally, Parametric Portfolio Associates LLC bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $217,000. Institutional investors own 62.30% of the company’s stock.

About Ventyx Biosciences (Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.

Further Reading

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.